The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

The human skin is home to a wide variety of bacteria. The composition of the community of bacteria—called the "skin microbiota"—has serious ...

The company’s ENS-002 is aimed at treating atopic dermatitis. Credit: © 2024 Concerto Biosciences, Inc. All rights reserved.

Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...

Researchers assessed the prevalence of occupational allergic contact dermatitis and characterized common occupational allergens in a cohort of construction workers.

Eli Lilly Canada Inc. (Lilly Canada) is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...